ImmunoPrecise Antibodies ( (IPA) ) just unveiled an update.
ImmunoPrecise Antibodies Ltd. has entered a strategic partnership with a leading biotechnology company to develop novel cancer therapeutics, valued initially at $8 million with potential expansion to $10 million. This collaboration will leverage IPA’s proprietary B-cell Select™ platform and AI-driven discovery capabilities to enhance the development of Antibody-Drug Conjugates and bispecific antibodies, aiming to streamline the path from target discovery to preclinical candidate selection, thereby advancing next-generation biologics for cancer treatment.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company utilizes multi-omics modeling and complex artificial intelligence through proprietary and patented technologies, offering an integrated suite of capabilities to address complex industry challenges. It operates with several subsidiaries in North America and Europe.
YTD Price Performance: -19.33%
Average Trading Volume: 7,423,770
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.28M
Find detailed analytics on IPA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com